These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

237 related articles for article (PubMed ID: 20688160)

  • 1. Pharmacokinetic evaluation of doxorubicin plasma levels in normal and overweight patients with breast cancer and simulation of dose adjustment by different indexes of body mass.
    Barpe DR; Rosa DD; Froehlich PE
    Eur J Pharm Sci; 2010 Nov; 41(3-4):458-63. PubMed ID: 20688160
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pharmacokinetics of low-dose doxorubicin and metabolites in patients with AIDS-related Kaposi sarcoma.
    Joerger M; Huitema AD; Meenhorst PL; Schellens JH; Beijnen JH
    Cancer Chemother Pharmacol; 2005 May; 55(5):488-96. PubMed ID: 15726371
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Population pharmacokinetics of doxorubicin: establishment of a NONMEM model for adults and children older than 3 years.
    Kontny NE; Würthwein G; Joachim B; Boddy AV; Krischke M; Fuhr U; Thompson PA; Jörger M; Schellens JH; Hempel G
    Cancer Chemother Pharmacol; 2013 Mar; 71(3):749-63. PubMed ID: 23314734
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Investigation of the influence of modulation of P-glycoprotein by a multiple dosing regimen of tamoxifen on the pharmacokinetics and toxicodynamics of doxorubicin.
    Darvari R; Boroujerdi M
    Cancer Chemother Pharmacol; 2005 Nov; 56(5):497-509. PubMed ID: 15937726
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Phase I pharmacokinetic study of cyclosporin A combined with doxorubicin.
    Erlichman C; Moore M; Thiessen JJ; Kerr IG; Walker S; Goodman P; Bjarnason G; DeAngelis C; Bunting P
    Cancer Res; 1993 Oct; 53(20):4837-42. PubMed ID: 8402670
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pharmacokinetics of duloxetine hydrochloride enteric-coated tablets in healthy Chinese volunteers: a randomized, open-label, single- and multiple-dose study.
    Zhao RK; Cheng G; Tang J; Song J; Peng WX
    Clin Ther; 2009 May; 31(5):1022-36. PubMed ID: 19539103
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A novel doxorubicin-glucuronide prodrug DOX-GA3 for tumour-selective chemotherapy: distribution and efficacy in experimental human ovarian cancer.
    Houba PH; Boven E; van der Meulen-Muileman IH; Leenders RG; Scheeren JW; Pinedo HM; Haisma HJ
    Br J Cancer; 2001 Feb; 84(4):550-7. PubMed ID: 11207053
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pharmacokinetics of intravenously administered stealth liposomal doxorubicin modulated with verapamil in rats.
    Wang JC; Liu XY; Lu WL; Chang A; Zhang Q; Goh BC; Lee HS
    Eur J Pharm Biopharm; 2006 Jan; 62(1):44-51. PubMed ID: 16126379
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Pharmacokinetic profile of high-dose doxorubicin administered during a 6 h intravenous infusion in breast cancer patients].
    Wihlm J; Limacher JM; Levêque D; Duclos B; Dufour P; Bergerat JP; Methlin G
    Bull Cancer; 1997 Jun; 84(6):603-8. PubMed ID: 9295863
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Targeting therapy of magnetic doxorubicin liposome in nude mice bearing colon cancer].
    Zhou PH; Yao LQ; Qin XY; Shen XZ; Liu YS; Lu WY; Yao M
    Zhonghua Yi Xue Za Zhi; 2003 Dec; 83(23):2073-6. PubMed ID: 14703420
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Preparation of doxorubicin-loaded chitosan polymeric micelle and study on its tissue biodistribution in mice].
    Xu XY; Zhou JP; Li L; Zhang Y; Huo MR; Wang X; Lü L
    Yao Xue Xue Bao; 2008 Jul; 43(7):743-8. PubMed ID: 18819480
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pharmacokinetics of intra-arterial mitomycin C in the chemoembolization treatment of liver metastases with polyvinylalcohol or degradable starch microspheres.
    Rump AF; Woschée U; Theisohn M; Fischbach R; Heindel W; Lackner K; Klaus W
    Eur J Clin Pharmacol; 2002 Oct; 58(7):459-65. PubMed ID: 12389068
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Accelerator mass spectrometry allows for cellular quantification of doxorubicin at femtomolar concentrations.
    DeGregorio MW; Dingley KH; Wurz GT; Ubick E; Turteltaub KW
    Cancer Chemother Pharmacol; 2006 Feb; 57(3):335-42. PubMed ID: 16047147
    [TBL] [Abstract][Full Text] [Related]  

  • 14. An open-label study to evaluate dose and cycle dependence of the pharmacokinetics of pegylated liposomal doxorubicin.
    Gabizon A; Isacson R; Rosengarten O; Tzemach D; Shmeeda H; Sapir R
    Cancer Chemother Pharmacol; 2008 Apr; 61(4):695-702. PubMed ID: 17549475
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Association of high-dose cyclophosphamide, cisplatin, and carmustine pharmacokinetics with survival, toxicity, and dosing weight in patients with primary breast cancer.
    Petros WP; Broadwater G; Berry D; Jones RB; Vredenburgh JJ; Gilbert CJ; Gibbs JP; Colvin OM; Peters WP
    Clin Cancer Res; 2002 Mar; 8(3):698-705. PubMed ID: 11895898
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pharmacokinetics of Bcl-2 antisense oligonucleotide (G3139) combined with doxorubicin in SCID mice bearing human breast cancer solid tumor xenografts.
    Lopes de Menezes DE; Mayer LD
    Cancer Chemother Pharmacol; 2002 Jan; 49(1):57-68. PubMed ID: 11855753
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Human pharmacokinetic characterization and in vitro study of the interaction between doxorubicin and paclitaxel in patients with breast cancer.
    Gianni L; Viganò L; Locatelli A; Capri G; Giani A; Tarenzi E; Bonadonna G
    J Clin Oncol; 1997 May; 15(5):1906-15. PubMed ID: 9164201
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pharmacokinetics of oxaliplatin (NSC 266046) alone and in combination with paclitaxel in cancer patients.
    Liu J; Kraut E; Bender J; Brooks R; Balcerzak S; Grever M; Stanley H; D'Ambrosio S; Gibson-D'Ambrosio R; Chan KK
    Cancer Chemother Pharmacol; 2002 May; 49(5):367-74. PubMed ID: 11976830
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pharmacokinetics of intravenous etoposide in patients with breast cancer: influence of dose escalation and cyclophosphamide and doxorubicin coadministration.
    Busse D; Würthwein G; Hinske C; Hempel G; Fromm MF; Eichelbaum M; Kroemer HK; Busch FW
    Naunyn Schmiedebergs Arch Pharmacol; 2002 Sep; 366(3):218-25. PubMed ID: 12172704
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Update: the M.D. Anderson Cancer Center experience with paclitaxel in the management of breast carcinoma.
    Holmes FA
    Semin Oncol; 1995 Aug; 22(4 Suppl 8):9-15. PubMed ID: 7543702
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.